Damon J A Toth1,2,3, Matthew H Samore1,2, Richard E Nelson1,2. 1. Department of Veterans Affairs Salt Lake City Health Care System, Salt Lake City, UT, USA. 2. Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA. 3. Department of Mathematics, University of Utah, Salt Lake City, UT, USA.
Abstract
BACKGROUND: Antibiotics designed to decolonize carriers of drug-resistant organisms could offer substantial population health benefits, particularly if they can help avert outbreaks by interrupting person-to-person transmission chains. However, cost effectiveness of an antibiotic is typically evaluated only according to its benefits to recipients, which can be difficult to demonstrate for carriers of an organism that may not pose an immediate health threat to the carrier. METHODS: We developed a mathematical transmission model to quantify the effects of 2 hypothetical antibiotics targeting carbapenem-resistant Enterobacteriaceae (CRE) among long-term acute care hospital inpatients: one assumed to decrease the death rate of patients with CRE bloodstream infections (BSIs) and the other assumed to decolonize CRE carriers after clinical detection. We quantified the effect of each antibiotic on the number of BSIs and deaths among patients receiving the drug (direct effect) and among all patients (direct and indirect effect) compared to usual care. We applied these results to a cost-effectiveness analysis with effectiveness outcome of life-years gained and assumed costs for antibiotic doses and for CRE BSI. RESULTS: The decolonizing antibiotic, once indirect effects were included, produced increased relative effectiveness and decreased relative costs compared to both usual care and the BSI treatment antibiotic. In fact, in most scenarios, the decolonizing drug was the dominant treatment strategy (ie, less costly and more effective). CONCLUSIONS: Antibiotics that decolonize carriers of drug-resistant organisms can be highly cost-effective when considering indirect benefits within populations vulnerable to outbreaks. Public health could benefit from finding ways to incentivize development of decolonizing antibiotics in the US, where drugs with unclear direct benefits to recipients would pose difficulties in achieving FDA approval and financial benefit to the developer.
BACKGROUND: Antibiotics designed to decolonize carriers of drug-resistant organisms could offer substantial population health benefits, particularly if they can help avert outbreaks by interrupting person-to-person transmission chains. However, cost effectiveness of an antibiotic is typically evaluated only according to its benefits to recipients, which can be difficult to demonstrate for carriers of an organism that may not pose an immediate health threat to the carrier. METHODS: We developed a mathematical transmission model to quantify the effects of 2 hypothetical antibiotics targeting carbapenem-resistant Enterobacteriaceae (CRE) among long-term acute care hospital inpatients: one assumed to decrease the death rate of patients with CRE bloodstream infections (BSIs) and the other assumed to decolonize CRE carriers after clinical detection. We quantified the effect of each antibiotic on the number of BSIs and deaths among patients receiving the drug (direct effect) and among all patients (direct and indirect effect) compared to usual care. We applied these results to a cost-effectiveness analysis with effectiveness outcome of life-years gained and assumed costs for antibiotic doses and for CRE BSI. RESULTS: The decolonizing antibiotic, once indirect effects were included, produced increased relative effectiveness and decreased relative costs compared to both usual care and the BSI treatment antibiotic. In fact, in most scenarios, the decolonizing drug was the dominant treatment strategy (ie, less costly and more effective). CONCLUSIONS: Antibiotics that decolonize carriers of drug-resistant organisms can be highly cost-effective when considering indirect benefits within populations vulnerable to outbreaks. Public health could benefit from finding ways to incentivize development of decolonizing antibiotics in the US, where drugs with unclear direct benefits to recipients would pose difficulties in achieving FDA approval and financial benefit to the developer.
Authors: Laurence S J Roope; Richard D Smith; Koen B Pouwels; James Buchanan; Lucy Abel; Peter Eibich; Christopher C Butler; Pui San Tan; A Sarah Walker; Julie V Robotham; Sarah Wordsworth Journal: Science Date: 2019-04-05 Impact factor: 47.728
Authors: Mary K Hayden; Michael Y Lin; Karen Lolans; Shayna Weiner; Donald Blom; Nicholas M Moore; Louis Fogg; David Henry; Rosie Lyles; Caroline Thurlow; Monica Sikka; David Hines; Robert A Weinstein Journal: Clin Infect Dis Date: 2014-12-23 Impact factor: 9.079
Authors: Frederic S Zimmerman; Marc V Assous; Tali Bdolah-Abram; Tamar Lachish; Amos M Yinnon; Yonit Wiener-Well Journal: Am J Infect Control Date: 2013-03 Impact factor: 2.918
Authors: Michael Y Lin; Rosie D Lyles-Banks; Karen Lolans; David W Hines; Joel B Spear; Russell Petrak; William E Trick; Robert A Weinstein; Mary K Hayden Journal: Clin Infect Dis Date: 2013-08-14 Impact factor: 9.079
Authors: Rachel B Slayton; Damon Toth; Bruce Y Lee; Windy Tanner; Sarah M Bartsch; Karim Khader; Kim Wong; Kevin Brown; James A McKinnell; William Ray; Loren G Miller; Michael Rubin; Diane S Kim; Fred Adler; Chenghua Cao; Lacey Avery; Nathan T B Stone; Alexander Kallen; Matthew Samore; Susan S Huang; Scott Fridkin; John A Jernigan Journal: MMWR Morb Mortal Wkly Rep Date: 2015-08-07 Impact factor: 17.586
Authors: John P Hays; Maria Jose Ruiz-Alvarez; Natalia Roson-Calero; Rohul Amin; Jayaseelan Murugaiyan; Maarten B M van Dongen Journal: Infect Dis Ther Date: 2022-05-23